BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27371671)

  • 1. MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.
    Marine JC; Jochemsen AG
    Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27371671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Roles of MDM2 and MDMX in Cancer.
    Karni-Schmidt O; Lokshin M; Prives C
    Annu Rev Pathol; 2016 May; 11():617-44. PubMed ID: 27022975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roles and regulation of MDM2 and MDMX: it is not just about p53.
    Klein AM; de Queiroz RM; Venkatesh D; Prives C
    Genes Dev; 2021 May; 35(9-10):575-601. PubMed ID: 33888565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.
    Biderman L; Poyurovsky MV; Assia Y; Manley JL; Prives C
    Mol Cell Biol; 2012 Apr; 32(7):1214-25. PubMed ID: 22290440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 binds the mdmx mRNA and controls its translation.
    Tournillon AS; López I; Malbert-Colas L; Findakly S; Naski N; Olivares-Illana V; Karakostis K; Vojtesek B; Nylander K; Fåhraeus R
    Oncogene; 2017 Feb; 36(5):723-730. PubMed ID: 27375027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
    Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.
    Jacob AG; Singh RK; Comiskey DF; Rouhier MF; Mohammad F; Bebee TW; Chandler DS
    PLoS One; 2014; 9(8):e104444. PubMed ID: 25105592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
    Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
    Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2, MDMX and p53 in oncogenesis and cancer therapy.
    Wade M; Li YC; Wahl GM
    Nat Rev Cancer; 2013 Feb; 13(2):83-96. PubMed ID: 23303139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
    Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.
    Ohtsubo C; Shiokawa D; Kodama M; Gaiddon C; Nakagama H; Jochemsen AG; Taya Y; Okamoto K
    Cancer Sci; 2009 Jul; 100(7):1291-9. PubMed ID: 19432880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner.
    Zhang Y; Zeng SX; Hao Q; Lu H
    Dev Biol; 2017 Mar; 423(1):34-45. PubMed ID: 28118981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mdmx and Mdm2: brothers in arms?
    Marine JC; Jochemsen AG
    Cell Cycle; 2004 Jul; 3(7):900-4. PubMed ID: 15254433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
    Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
    Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.